PARP Inhibitor Approved as Adjuvant Treatment for High-risk, Early Breast Cancer
The FDA approved olaparib for patients with breast cancer who have inherited BRCA mutations and have received prior neoadjuvant or adjuvant chemotherapy The U.S. Food and Drug Administration (FDA) has approved the PARP inhibitor...